From Mechanism to Clinical Effects -
The similarities and differences between TKIs and anti-VEGF antibody

Summary
1. Anti-angiogenic drugs have different safety and efficacy profiles according to their pharmacologic effects
2. Hypertension, proteinuria, and bleeding risk may be the class effect of VEGFR inhibition
3. Off-target effects of TKIs may be associated with more GI or skin-related AEs
4. Adding bevacizumab to atezolizumab is proved to enhance the antitumor effects of immunotherapy
5. Whether other combinational therapy may yield similar efficacy require more studies